Geode Capital Management LLC Increases Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Geode Capital Management LLC increased its position in Nurix Therapeutics, Inc. ( NASDAQ:NRIX – Free Report ) by 9.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission.

The firm owned 1,585,127 shares of the company’s stock after buying an additional 137,087 shares during the quarter. Geode Capital Management LLC’s holdings in Nurix Therapeutics were worth $29,870,000 as of its most recent filing with the Securities and Exchange Commission. A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company.



Y Intercept Hong Kong Ltd purchased a new position in shares of Nurix Therapeutics in the 3rd quarter worth about $346,000. Barclays PLC increased its position in Nurix Therapeutics by 77.9% during the 3rd quarter.

Barclays PLC now owns 128,344 shares of the company’s stock worth $2,884,000 after purchasing an additional 56,190 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its holdings in Nurix Therapeutics by 8.4% in the third quarter.

Teachers Retirement System of The State of Kentucky now owns 30,024 shares of the company’s stock valued at $675,000 after buying an additional 2,329 shares during the period. Franklin Resources Inc. lifted its position in Nurix Therapeutics by 52.

4% during the third quarter. Franklin Resources Inc. now owns 123,101 shares of the company’s stock valued at $2,766,000 after buying an additional 42,315 shares in the last quarter.

Finally, Lord Abbett & CO. LLC acquired a new position in Nurix Therapeutics during the third quarter valued at approximately $7,879,000. Wall Street Analysts Forecast Growth Several equities research analysts have recently issued reports on the stock.

Stifel Nicolaus dropped their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, April 9th.

Leerink Partnrs raised Nurix Therapeutics to a “hold” rating in a research report on Monday, March 17th. Morgan Stanley upped their target price on Nurix Therapeutics from $16.00 to $17.

00 and gave the stock an “equal weight” rating in a research report on Monday, February 3rd. Royal Bank of Canada increased their target price on Nurix Therapeutics from $26.00 to $27.

00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Finally, Wells Fargo & Company decreased their price target on Nurix Therapeutics from $32.00 to $25.

00 and set an “overweight” rating for the company in a report on Wednesday, April 9th. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.

com, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.44. Insider Buying and Selling In related news, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction dated Thursday, January 30th.

The shares were sold at an average price of $19.85, for a total transaction of $73,246.50.

Following the sale, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. This represents a 6.

19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink . Also, CFO Houte Hans Van sold 2,811 shares of the firm’s stock in a transaction dated Thursday, January 30th.

The stock was sold at an average price of $19.85, for a total transaction of $55,798.35.

Following the completion of the transaction, the chief financial officer now directly owns 39,549 shares in the company, valued at $785,047.65. This represents a 6.

64 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold 12,326 shares of company stock worth $213,449 over the last ninety days.

7.20% of the stock is owned by insiders. Nurix Therapeutics Stock Performance Shares of NRIX stock opened at $9.

80 on Thursday. The stock has a market capitalization of $747.11 million, a price-to-earnings ratio of -3.

39 and a beta of 2.23. Nurix Therapeutics, Inc.

has a one year low of $8.18 and a one year high of $29.56.

The company’s 50-day simple moving average is $13.48 and its 200-day simple moving average is $18.94.

Nurix Therapeutics ( NASDAQ:NRIX – Get Free Report ) last released its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.

72) by $0.05. The company had revenue of $18.

45 million for the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.

65% and a negative net margin of 354.85%. During the same quarter last year, the business posted ($0.

76) EPS. As a group, research analysts forecast that Nurix Therapeutics, Inc. will post -2.

99 EPS for the current year. Nurix Therapeutics Company Profile ( Free Report ) Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

See Also Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. ( NASDAQ:NRIX – Free Report ).

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..